Format

Send to

Choose Destination
Nurs Womens Health. 2016 Jun-Jul;20(3):309-14. doi: 10.1016/j.nwh.2016.03.002.

Flibanserin and Female Sexual Desire.

Author information

1
College of Health Sciences, School of Nursing at the University of Massachusetts Lowell in Lowell, MA; Health Quarters in Beverly, MA.. Electronic address: heidi_fantasia@uml.edu.

Abstract

Female hypoactive sexual desire disorder (HSDD) is one type of sexual problem that can affect women. It is characterized by low or absent sexual desire that cannot be attributed to another cause and results in difficulty in interpersonal relationships. HSDD is not well understood, and women may not report symptoms of difficulties to their health care providers. In August 2015, the U.S. Food and Drug Administration approved flibanserin, a nonhormonal oral medication for the treatment of HSDD in premenopausal women. Flibanserin is the only currently available pharmacologic treatment for HSDD. This article will provide an overview of flibanserin, including potential adverse reactions, special considerations for use, and implications for nursing practice.

KEYWORDS:

female hypoactive sexual desire disorder; female sexual interest/arousal disorder; flibanserin

PMID:
27287358
DOI:
10.1016/j.nwh.2016.03.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center